A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer
Open Access
- 1 August 2013
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 8 (8) , 1091-1094
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Histone Deacetylase InhibitorsJournal of Thoracic Oncology, 2011
- Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene ExpressionMolecular Cancer Therapeutics, 2010
- The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cellsin vitroandin vivowith particular efficacy for small cell lung cancerMolecular Cancer Therapeutics, 2009
- Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cellsMolecular Cancer Therapeutics, 2007
- HDAC inhibitors overcome first hurdleNature Biotechnology, 2007
- Histone Deacetylase Inhibitors: Biology and Mechanism of ActionThe Cancer Journal, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Chemotherapy for small cell lung cancerSeminars in Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000